arcoris bio, a Swiss life science research tools and in vitro diagnostics company, today announced the launch of its immunoMUSE^® kits, based on its breakthrough MUSE^® biomarker detection platform. With immunoMUSE^®, researchers can create their own multiplex immunofluorescence panels using their preferred antibodies, combining flexibility with high sensitivity and ease of use.

arcoris bio’s MUSE^® technology enables simultaneous detection of multiple biomarkers with exceptional sensitivity and simplified workflows. By supporting the detection of low-abundance targets within a single sample and enabling higher throughput, MUSE^® is well positioned to advance applications in digital pathology and translational research.

“With immunoMUSE^®, we put control over multiplex panel design directly into the hands of researchers,” said Simon Restrepo, CSO at arcoris bio. “Users can now leverage their own validated antibodies while benefiting from the sensitivity, scalability, and simplicity of the MUSE^® platform.”

arcoris bio will present immunoMUSE^® at the European Association for Cancer Research (EACR) Annual Congress 2026, taking place June 8-11 in Budapest, Hungary. Attendees are invited to visit the arcoris bio team at booth 63 to learn more and discuss with the experts how MUSE^® is shaping the future of biomarker detection.